How to Solve the Jobs Dilemma: Attract and Retain More Entrepreneurs
- Apr 14
- North America
The eye-popping price tag for the hepatitis C drug Sovaldi has insurers and patient advocates up in arms. The fault doesn’t rest with drugmaker Gilead, Wharton experts say, but with the U.S. health care system as a whole.
-
Sovaldi: Who’s to Blame for the $1,000 a Day Cure?
The eye-popping price tag for the hepatitis C drug Sovaldi has insurers and patient advocates up in arms. The fault doesn’t rest with drugmaker Gilead, Wharton experts say, but with the U.S. health care system as a whole.
-
China’s Ticking Debt Bomb
Amid predictions that China’s GDP growth rate will slow to 7.5% this year, a recent report by Morgan Stanley suggests that the country will soon experience a “disorderly unwind” of private sector and local government debt.
-
High-frequency Trading: Profiting from News
Technological advances are changing the playing field for investors, allowing for high-frequency trading that can skirt the spirit or letter of the law. But they also allow for practices that can make the market more efficient, new Wharton research shows.
Knowledge@Wharton Partners